ADAPTOGEN SCIENCE / PRECISION RESILIENCE NUTRITION

Understanding Adaptogens

From Ancient Tonics to Precision Resilience Nutrition

Why the next generation of adaptogenic products should be designed around measurable resilience - not simply around "stress reduction".

Core thesis

Stress resilience = effective response + preserved function + efficient recovery.

José M. López, BSc, MD, PhD, LLD (C)

Scientific & Technical Article | August 2026 | English edition

ABSTRACT

Few categories in contemporary nutrition illustrate the tension between traditional knowledge, modern pharmacology and consumer marketing as clearly as adaptogens. Ashwagandha, rhodiola, ginseng, schisandra, eleuthero and holy basil are increasingly incorporated into dietary supplements, functional beverages, gummies, shots and performance products intended to support stress management, energy, sleep, cognition or general wellbeing. Yet "adaptogen" remains an unusual scientific concept. It is neither a universally accepted pharmacological class nor a regulatory category comparable with vitamins, minerals or authorised medicines. Even the European Medicines Agency (EMA), which has published a formal reflection paper on the adaptogenic concept, acknowledges the unresolved nature of its pharmacological definition.

This ambiguity should not be interpreted as evidence that adaptogens are biologically meaningless. Rather, it exposes a fundamental difficulty: adaptation is not a single biochemical pathway. It is a systems-level property involving neuroendocrine regulation, autonomic balance, cellular stress signalling, mitochondrial function, immune regulation, sleep, cognition and behaviour.

The scientific opportunity therefore lies not in asking whether a botanical "reduces stress", but whether it improves an organism's capacity to respond to, function during, and recover from stress without causing disproportionate physiological disruption.

This article proposes a transition from Adaptogens 1.0, based largely on traditional use and broad botanical identity, toward Adaptogens 3.0: precision resilience nutrition, where ingredients and combinations are selected according to defined stress phenotypes, chemically standardised, clinically validated under appropriate stress conditions and assessed using multidimensional physiological and functional endpoints.

The result could transform adaptogens from an attractive but scientifically diffuse marketing category into one of the most interesting fields of systems-oriented nutritional science.

Keywords: *adaptogens; stress; resilience; allostasis; hormesis; HPA axis; ashwagandha; Rhodiola rosea; ginseng; phytochemicals; nutraceuticals; functional foods; precision nutrition.*

THE ARTICLE IN FOUR IDEAS

1

Adaptation is not stress suppression

The scientifically interesting endpoint is better regulation, preserved function and faster recovery - not indiscriminate dampening of stress biology.

2

The extract is the intervention

Botanical species alone does not establish equivalence. Identity, plant part, extraction process, markers, fingerprint, stability and contaminants matter.

3

Challenge-based trials are needed

If adaptogens are meant to improve adaptation, the stress challenge and recovery phase should be built into clinical design.

4

The future is precision resilience

Stress phenotype, timing, dose, delivery system, wearables, longitudinal data and AI can move the category beyond generic "stress support".

1. Adaptogens Are Not Simply "Herbs for Stress"

The popular definition of an adaptogen is deceptively simple: a natural substance that helps the body cope with stress. Scientifically, that description is inadequate.

Stress is not a single condition. Sleep deprivation, psychological pressure, infection, intense exercise, caloric restriction, environmental heat, cognitive overload and chronic occupational stress generate overlapping but different physiological responses. An ingredient capable of reducing subjective anxiety is therefore not automatically equivalent to one that preserves attention during sleep deprivation or improves recovery following intense physical exercise.

A sedative may make someone feel less stressed while simultaneously reducing performance. A stimulant may increase performance while exacerbating sympathetic activation. A true adaptogenic effect, in the classical interpretation, should do something different: increase functional tolerance to a stressor while limiting maladaptive physiological consequences.

Historically, the concept is also more complicated than the frequently repeated narrative that adaptogens are simply ancient Eastern remedies rediscovered by Western science. Many plants now described as adaptogens indeed originate from Ayurveda, Traditional Chinese Medicine and Eurasian ethnomedicine. However, the actual term adaptogen emerged from Soviet pharmacological research in the twentieth century and was subsequently refined into the concept of increasing "non-specific resistance" to stress (Panossian et al., 2021).

Traditional knowledge supplied many of the plants. Modern stress physiology supplied the hypothesis. Clinical science must now determine which parts of that hypothesis are correct.

2. The Real Biological Target Is Not Stress. It Is Adaptive Capacity.

The human organism is not designed to eliminate stress. It is designed to respond to it.

Acute stress activates a coordinated biological programme involving:

- the hypothalamic-pituitary-adrenal (HPA) axis;
- cortisol and other glucocorticoids;
- the sympathetic nervous system;
- catecholamines;
- cardiovascular adaptation;
- glucose mobilisation;
- immune signalling;
- mitochondrial energy production;
- inflammatory mediators;
- sleep-wake regulation;
- attention and threat detection.

These systems are not pathological. They are essential for survival. The problem arises when activation becomes excessive, prolonged or insufficiently resolved. This leads to the concept of allostatic load: the cumulative physiological cost of repeatedly maintaining stability through adaptation.

In this context, the objective of an adaptogen should not be to suppress the stress response indiscriminately. It should be to improve its efficiency.

WORKING MODEL

Stress resilience = effective response + preserved function + efficient recovery.

The best future adaptogenic products may therefore be those that do not produce the largest immediate biochemical change, but rather those that improve the quality and trajectory of recovery following a defined challenge.

3. From Homeostasis to Allostasis

Traditional pharmacology often imagines physiological regulation as homeostasis: the maintenance of variables around relatively stable set points. Modern stress physiology is more dynamic. The organism frequently maintains stability by changing itself.

Heart rate increases. Glucose availability rises. Attention narrows. Cortisol changes. Inflammatory activity can change. Sleep architecture may subsequently compensate. This process - stability through change - is described as allostasis.

Adaptogens fit this model better than they fit classical "one molecule-one receptor-one effect" pharmacology. Botanical extracts contain multiple bioactive constituents acting across interconnected biological networks. Systems pharmacology, network biology and stress-response modelling may therefore be more appropriate frameworks than traditional reductionist pharmacology for understanding at least some of their effects.

This does not mean that complexity proves efficacy. Complexity is not evidence. It simply means that the experimental methods used to investigate complex botanical interventions must reflect the biological hypothesis being tested.

4. The Hormesis Hypothesis

One particularly interesting model involves hormesis. Hormesis describes situations in which a mild challenge activates protective cellular responses that subsequently increase resistance to a greater challenge.

Exercise is perhaps the most familiar example. Exercise temporarily increases oxidative, energetic and mechanical stress. Yet repeated exposure stimulates mitochondrial biogenesis, antioxidant defence, cardiovascular adaptation and metabolic resilience.

Some adaptogenic phytochemicals may behave as mild biological stress signals themselves. Rather than functioning simply as antioxidants that chemically neutralise reactive species, they may activate endogenous defence pathways.

Proposed mechanisms include modulation of:

- heat-shock proteins such as HSP70;
- FOXO transcription factors;
- JNK stress signalling;
- Nrf2-dependent cellular defence;
- AMPK;
- PI3K/Akt signalling;
- nitric oxide pathways;
- neuropeptide Y;
- glucocorticoid signalling;
- mitochondrial stress responses.

Experimental and systems-level studies support several of these pathways, although much of the mechanistic evidence remains preclinical and should not be confused with demonstrated human clinical efficacy (Panossian & Wikman, 2010).

Some adaptogens may not simply block stress. They may partially train stress-response systems.

5. A More Demanding Definition of an Adaptogen

The supplement industry would benefit from abandoning the idea that any traditional tonic automatically qualifies as an adaptogen. A scientifically useful adaptogen should ideally fulfil four conditions.

1. Stress-contingent efficacy

Its benefit should become especially evident when the organism is challenged. An ingredient that improves performance equally in rested and stressed subjects may simply be a stimulant, nootropic or ergogenic compound.

2. Preservation of function

The intervention should preserve relevant performance: cognition, endurance, attention, sleep recovery, emotional regulation or physical output.

3. Improvement in recovery or physiological regulation

Evidence should demonstrate improvement in one or more regulatory systems rather than simply altering a biomarker.

4. Acceptable safety during intended use

An intervention cannot meaningfully increase resilience if its pharmacological activity creates comparable or greater risks elsewhere. This requirement has become especially important as adaptogenic ingredients have moved from occasional traditional use into concentrated extracts consumed daily by millions of people.

6. The Main Adaptogens: What Does the Evidence Actually Say?

The evidence base is highly uneven. Calling ingredients "adaptogens" as though they belonged to one homogeneous class obscures this reality.

Botanical	Principal compounds commonly monitored	Most plausible current application	Human evidence	Key limitation
Withania somnifera	Withanolides	Chronic stress, sleep, anxiety-related symptoms	Moderate and expanding	Extract heterogeneity; emerging safety questions
Rhodiola rosea	Rosavins, salidroside	Fatigue, mental performance under stress, endurance	Moderate but heterogeneous	Product authenticity and inconsistent trials
Panax ginseng	Ginsenosides	Fatigue, physical/cognitive performance	Moderate-to-limited	Preparation-specific effects
Eleutherococcus senticosus	Eleutherosides	Fatigue and stress tolerance	Limited modern evidence	Much evidence is historical
Schisandra chinensis	Schisandrins/lignans	Physical and cellular stress resilience	Mechanistically interesting; clinical evidence limited	Insufficient large RCTs
Ocimum tenuiflorum	Eugenol, ursolic acid and others	Psychological stress/wellbeing	Preliminary	Small evidence base
Bacopa monnieri	Bacosides	Memory/cognition	Reasonable evidence for cognition	Better considered a cognitive botanical than a classical adaptogen

Modern reviews continue to place these plants within the adaptogenic literature, but the depth of human evidence differs substantially between species and preparations.

7. Ashwagandha: The Current Market Leader - and the Best Example of Why Nuance Matters

Withania somnifera has become almost synonymous with adaptogens in Western supplement markets. Its traditional Ayurvedic use is extensive, and modern clinical research has expanded rapidly.

A 2024 systematic review and meta-analysis of nine randomised trials involving 558 participants reported improvements in perceived stress, anxiety scores and cortisol relative to placebo (Arumugam et al., 2024). Other systematic reviews suggest possible improvements in sleep, particularly among people with insomnia and with interventions lasting approximately eight weeks or longer.

More recent 2026 meta-analytic work also supports endocrine activity, including reductions in cortisol, although heterogeneity between preparations remains substantial (Fornalik et al., 2026).

But this is precisely where scientific interpretation becomes interesting. A later meta-analysis reported significant reductions in cortisol without a statistically significant reduction in perceived stress. In other words: the biomarker improved while the subjective experience did not clearly improve.

> **Cortisol is not stress. Cortisol is one mediator within a dynamic stress-response system.**

8. The Cortisol Fallacy

A widespread commercial error is to assume: high cortisol = stress, therefore lower cortisol = successful stress reduction. Human physiology is not that simple.

Cortisol has circadian rhythms, a cortisol awakening response, pulsatile secretion, acute responses to physical and psychological stimuli, metabolic functions and immune regulatory functions. Persistently inappropriate cortisol signalling can certainly accompany chronic stress. But indiscriminately suppressing cortisol would not represent improved resilience.

Future adaptogen studies should therefore stop relying excessively on isolated morning cortisol measurements. More informative approaches include:

- cortisol awakening response;
- diurnal cortisol slope;
- repeated salivary sampling;
- challenge-induced cortisol response;
- recovery kinetics.

> **The real question is not "Did cortisol decrease?" It is "Did stress physiology become better regulated?"**

9. Rhodiola: Perhaps the Most Conceptually "Adaptogenic" Botanical

Rhodiola rosea provides an interesting contrast. Its historical research frequently focused not on relaxation but on maintaining performance during fatigue or stress. Studies have investigated physicians working night shifts, students during examination periods, military-style populations and physically active subjects.

Although older systematic reviews identified methodological weaknesses and inconsistent findings, a 2025 meta-analysis of 26 randomised trials involving 668 participants reported modest improvements in endurance-related outcomes including VO2max, time to exhaustion and time-trial performance, while also identifying considerable heterogeneity (Wang et al., 2025).

Importantly, the EMA herbal monograph permits traditional medicinal use of Rhodiola rosea for temporary relief of stress symptoms such as fatigue and weakness, but bases this conclusion on long-standing traditional use rather than sufficient clinical efficacy evidence.

> **Traditional-use recognition is not equivalent to modern clinical proof.**

10. Product Identity May Matter as Much as Botanical Identity

Two bottles labelled Rhodiola rosea are not necessarily pharmacologically equivalent. Analyses of commercial rhodiola products have found substantial problems with authenticity, marker compound content and label accuracy. More recent investigations continue to report large variability in rosavin and salidroside concentrations and discrepancies between labelled products and expected botanical or chemical profiles.

> **Clinical evidence obtained with Extract A cannot automatically validate Extract B simply because both labels say Rhodiola rosea.**

The same principle applies to ashwagandha, ginseng and other chemically complex botanicals.

11. The Extract Is the Intervention

A botanical name is taxonomy. It is not a complete pharmaceutical specification. At minimum, a serious adaptogenic ingredient should define:

- species;
- plant part;
- geographical origin where relevant;
- extraction solvent;
- drug-to-extract ratio;
- native extract ratio;
- marker constituents;
- manufacturing process;
- residual solvent profile;
- contaminant profile;
- chromatographic fingerprint;
- stability specification.

A statement such as "500 mg Ashwagandha 10:1" contains considerably less pharmacological information than many consumers - and some formulators - assume. Extraction ratios alone cannot guarantee chemical equivalence.

12. Marker Standardisation Is Necessary, but Not Sufficient

Manufacturers often solve botanical variability by standardising extracts to one marker compound. Examples include withanolides, rosavins, salidroside, ginsenosides, eleutherosides and bacosides. This is useful, but it introduces another potential error: a marker is not necessarily the mechanism.

A botanical containing the correct percentage of one marker can still have an abnormal overall phytochemical composition. The stronger quality model is therefore:

> **botanical identity + quantitative markers + chromatographic fingerprint + contaminant control**

Orthogonal botanical identification and chromatographic methods such as HPTLC or HPLC become particularly important when processing removes the morphological characteristics of the plant material.

13. Beyond Ashwagandha and Rhodiola

Panax ginseng

Ginseng has one of the longest histories of tonic use and contains multiple ginsenosides with neuroendocrine, metabolic and immunological activities. Meta-analyses suggest modest effects on fatigue, but heterogeneity between studies, extracts and populations remains important.

Eleutherococcus senticosus

Siberian ginseng - despite not being a true Panax ginseng - was central to early Soviet adaptogen research. Its historical relevance is considerable. Its modern high-quality clinical evidence base is less impressive.

Schisandra chinensis

Schisandra contains lignans including schisandrins and has particularly interesting mechanistic research involving cellular stress responses, hepatic metabolism and heat-shock pathways. Human evidence, however, remains considerably weaker than its mechanistic reputation.

Holy basil

Ocimum tenuiflorum occupies an important place in traditional medicine and increasingly appears in modern stress formulations. Its clinical evidence is promising but still insufficient to place it in the same evidentiary category as the best-studied ashwagandha extracts.

14. Not Every "Adaptogen" Is Actually an Adaptogen

One of the greatest commercial distortions of the category has been semantic expansion. The word is now applied to medicinal mushrooms, nootropics, antioxidants, calming herbs, stimulants, traditional tonics and virtually any botanical marketed for wellbeing.

Lion's mane, for example, may be interesting in cognition. Reishi may have immunological properties. Bacopa has evidence relating to cognition. L-theanine can influence relaxation and attention. Magnesium contributes to normal nervous-system and psychological function. None of those statements automatically makes these compounds classical adaptogens.

> **Therapeutic adjacency is not taxonomic equivalence.**

15. The Next Scientific Step: Measure Resilience, Not Relaxation

Current trials frequently measure subjects before supplementation and several weeks afterward. That design may miss the defining property of an adaptogen. If an adaptogen is supposed to improve adaptation to challenge, the challenge itself should become part of the experimental model.

A future clinical trial could therefore expose participants to a controlled stressor:

- sleep restriction;
- cognitive multitasking;
- examination stress;
- prolonged exercise;
- heat;
- circadian disruption;
- repeated occupational workload.

Researchers would then examine three phases:

Phase 1 - Baseline

What is normal physiology?

Phase 2 - Challenge

How far does the system deviate?

Phase 3 - Recovery

How quickly and completely does it return?

The third phase may ultimately prove the most informative.

16. A Proposed New Framework: The Resilience Signature

For product-development purposes, we propose a multidimensional Resilience Signature Framework. This is a research framework, not an already validated diagnostic index.

Instead of asking whether a product "reduces stress", a study would measure several independent dimensions.

Domain	Possible measurement
Perceived stress	PSS or validated equivalent
Autonomic resilience	HRV, resting heart rate, recovery kinetics
Neuroendocrine regulation	Cortisol awakening response, diurnal slope, challenge response
Cognitive resilience	Reaction time, working memory, sustained attention under load
Emotional resilience	Validated mood/anxiety instruments
Sleep recovery	Actigraphy, sleep efficiency, latency, fragmentation
Physical resilience	Fatigue, time to exhaustion, recovery
Metabolic resilience	Glucose variability, lactate or other context-specific markers

Domain	Possible measurement
Inflammatory response	hsCRP/cytokines where scientifically justified
Functional recovery	Time required to return toward baseline after challenge

An intervention would be considered increasingly convincing as it improved several independent but physiologically coherent domains. This avoids the common trap of declaring success because a single laboratory parameter moved statistically.

17. The Adaptogen Paradox

There may be an important methodological paradox hidden inside existing clinical research. If an adaptogen improves the response to stress rather than baseline physiology, then enrolling healthy, well-rested subjects with little stress may minimise the observable effect.

Imagine testing an umbrella on days selected randomly throughout the year. The umbrella would appear useless on most days. Its value becomes obvious when it rains. Likewise, the pharmacological signal of an adaptogen may become more visible when subjects actually experience the biological condition it is supposed to help them tolerate.

Adaptogens should increasingly be tested under experimentally defined stress conditions.

18. From "Stress Supplements" to Stress Phenotypes

Another mistake is assuming that all stressed consumers require the same formulation. They do not. At least four practical stress phenotypes can be distinguished for product-development purposes.

Phenotype A - Hyperarousal

Characteristics may include difficulty switching off, sleep initiation problems, elevated subjective tension and rumination. The formulation objective is down-regulation and recovery, not stimulation.

Phenotype B - Cognitive depletion

Characteristics may include impaired concentration, decision fatigue, mental exhaustion and sustained workload. The objective becomes preservation of cognitive function under load.

Phenotype C - Physical fatigue

Characteristics may include intensive training, occupational exertion and prolonged physical workload. The formulation target becomes performance preservation and recovery.

Phenotype D - Mixed chronic stress

Characteristics may include poor sleep, fatigue, emotional stress and reduced cognitive performance. This phenotype may require a broader intervention, but it also creates the greatest temptation to formulate an indiscriminate multi-ingredient "kitchen sink". Precision should replace ingredient accumulation.

19. Adaptogenic Formulation Should Be Mechanistic, Not Decorative

Many commercial products combine ashwagandha, rhodiola, ginseng, reishi, holy basil, schisandra, vitamins, magnesium and amino acids in a single formula. This may look impressive on a label. Scientifically, it creates several problems.

- the dose of each botanical may become subtherapeutic;
- overlapping pharmacology makes attribution impossible;
- interactions become less predictable;
- clinical validation of the final composition becomes increasingly difficult;
- the consumer may be exposed to five active botanical systems when two would have been sufficient.

PREFERRED FORMULATION LOGIC

defined phenotype -> defined biological objective -> minimum effective combination

The alternative - maximising the number of fashionable ingredients per capsule - is visually attractive but scientifically weak.

20. Adaptogenic Synergy Must Be Demonstrated, Not Assumed

Botanical combinations are frequently described as "synergistic". Usually, synergy has not actually been demonstrated. True pharmacological synergy means that the combined effect exceeds what would be expected from the individual components. That requires experimental demonstration.

Nevertheless, rational combinations can be designed around functional complementarity: one component may support stress perception or sleep, another may preserve cognitive performance, and a third may provide a micronutrient function with an authorised physiological role. This is more defensible than stacking ingredients merely because all are described as adaptogens.

21. Chronoadaptogenics: A Research Frontier

Stress physiology is profoundly circadian. Cortisol, melatonin, body temperature, alertness, autonomic tone and metabolic regulation all vary across the day. Yet most adaptogen products provide identical dosing instructions regardless of time.

A future field of chronoadaptogenics could examine whether particular interventions are more appropriate:

- before anticipated stress;
- during sustained cognitive demand;
- after physical challenge;
- before sleep;
- during circadian disruption.

It is biologically plausible that an activating adaptogenic profile and a recovery-oriented adaptogenic profile should not necessarily be administered at the same time. Robust clinical evidence for such timing strategies remains insufficient. Chronoadaptogenics should therefore be considered a research hypothesis - not a marketing claim.

22. Delivery Format Is Part of the Pharmacology

Adaptogens have moved far beyond capsules. They now appear in gummies, functional beverages, coffees, teas, powders, oral sticks, chocolates, shots and sports products. This creates formulation challenges.

Gummies

Advantages include consumer compliance and a familiar format. Challenges include limited payload, taste masking, moisture stability and heat exposure during manufacture.

Functional beverages

Advantages include rapid consumption and lifestyle positioning. Challenges include solubility, sedimentation, flavour, oxidation, hydrolytic stability, botanical colour and microbial stability.

Shots

Advantages include meaningful botanical payload and premium positioning. Challenges include bitterness, astringency, concentrated flavour and physical stability.

Capsules

Capsules remain one of the most scientifically straightforward delivery systems when relatively high doses of standardised extracts are required.

The fashionable format should never determine the dose. The required dose should determine whether the format is technically appropriate.

23. "Enhanced Bioavailability" Requires Proof

Another emerging marketing layer involves liposomes, nanoparticles, phospholipid complexes, micelles and encapsulation technologies. These systems may genuinely improve solubility or absorption for particular phytochemicals. But increased absorption does not automatically mean increased clinical benefit.

For adaptogens, manufacturers should distinguish pharmaceutical performance from clinical performance. A formulation can demonstrate twice the plasma concentration of a marker compound and still fail to show twice the biological effect. Bioavailability claims therefore require their own evidence chain.

24. Safety: Natural Does Not Mean Pharmacologically Inert

The stronger the biological activity attributed to adaptogens, the less credible it becomes to simultaneously claim that they cannot produce meaningful adverse effects.

Ashwagandha illustrates the issue particularly well. The US National Center for Complementary and Integrative Health notes possible benefits for stress and insomnia, but also insufficient long-term safety data, possible drug interactions and rare reports of liver injury. The NIH LiverTox database considers clinically apparent liver injury attributable to ashwagandha a likely, although uncommon, phenomenon and describes predominantly cholestatic or mixed patterns appearing after several weeks of use. The German Federal Institute for Risk Assessment has adopted a cautious position, particularly regarding children, pregnancy, breastfeeding and people with liver disease.

Modern concentrated botanical supplements require modern pharmacovigilance.

This does not mean that ashwagandha should be characterised as intrinsically dangerous. It means that safety claims should be proportional to the intensity and duration of intended use.

25. Safety-by-Design Should Become Part of Adaptogenic Product Development

A serious manufacturer should maintain an ingredient-specific safety dossier containing:

- botanical identity;
- human exposure history;
- toxicology;
- adverse-event literature;
- drug-botanical interactions;
- vulnerable population exclusions;
- hepatic considerations;
- reproductive considerations;
- endocrine effects;
- allergen status;
- contaminant limits;
- post-market surveillance.

This is especially important when products are designed for chronic daily consumption. Adaptogens are often marketed precisely to consumers who expect to take them for months. Ironically, long-term exposure is frequently one of the least adequately studied dimensions.

26. The Regulatory Reality in Europe

Adaptogen marketing in Europe requires particular care. There is no general European regulatory category that permits a manufacturer simply to label a food supplement "adaptogenic" and make unrestricted physiological claims. Regulation (EC) No 1924/2006 governs nutrition and health claims made on foods.

Botanicals present an unusual situation because many Article 13 botanical-related claims remain "on hold" while European institutions continue to consider their regulatory treatment. This does not mean that any botanical claim is automatically legal.

Operators must still consider:

- the precise wording;
- national implementation;
- evidence;
- product classification;
- whether the communication implies prevention or treatment of disease;
- specific restrictions applicable in individual Member States.

Regulatory strategy therefore must be product- and market-specific.

27. Medicinal Use and Supplement Use Must Not Be Confused

The same botanical may exist simultaneously as a traditional herbal medicinal product, a food supplement, a botanical ingredient or a functional food component. Those categories have different regulatory requirements.

For example, the EMA recognises traditional medicinal use of Rhodiola rosea for temporary relief of stress symptoms such as fatigue and weakness. That medicinal monograph does not automatically authorise an identical claim for every rhodiola-containing food supplement.

Regulatory status follows the product, its presentation and applicable legislation - not simply the botanical name.

28. The United States: Different System, Same Need for Evidence

US dietary supplements operate under a different regulatory framework. Structure/function claims may describe how an ingredient supports normal structure or physiological function, provided applicable requirements are met and claims do not present the product as diagnosing, treating, curing or preventing disease. Manufacturers remain responsible for ensuring that claims are truthful and appropriately substantiated.

"supports healthy stress response" and "treats anxiety disorder" are not regulatory equivalents.

Language is part of product development.

29. The Future: Adaptogens 3.0

The field can be divided conceptually into three generations.

Adaptogens 1.0 - Traditional tonics

Selection based primarily on ethnobotanical history.

Adaptogens 2.0 - Standardised extracts

Botanical preparations characterised by chemical markers and evaluated in controlled trials.

Adaptogens 3.0 - Precision resilience systems

Products selected according to stress phenotype, validated botanical extract, mechanistic rationale, appropriate dose, timing, delivery system, challenge-based clinical validation and multidimensional physiological assessment.

Adaptogens 3.0 would no longer simply sell "calm". They would sell demonstrated functional resilience.

30. Wearables Could Transform Adaptogen Research

Consumer wearable technology provides an unprecedented opportunity. Devices can already estimate or measure heart rate, heart-rate variability, sleep duration, sleep continuity, activity, respiratory patterns, skin temperature and circadian behaviour.

None of these signals independently diagnoses stress. But longitudinal data may reveal something conventional trials often miss: how rapidly an individual returns toward their own baseline after repeated real-world challenges. That is much closer to resilience.

Future adaptogen trials could combine validated questionnaires, laboratory biomarkers, cognitive testing and wearable physiology to generate longitudinal stress-response profiles. This would move adaptogen science away from isolated snapshots and toward dynamic physiology.

31. Artificial Intelligence and Digital Phenotyping

The next step could involve machine-learning models capable of identifying individual stress-response phenotypes. Rather than asking "Did HRV improve?", a model could examine sleep, HRV, workload, activity, subjective stress, cognitive performance, environmental exposures and response to supplementation.

> **The relevant endpoint could become: Did the person's adaptive trajectory improve?**

This is an intriguing convergence between phytochemistry, nutraceutical science, digital health and systems biology. It also introduces major challenges around validation, algorithmic bias, privacy, reproducibility, medical-device classification and interpretation of consumer wearable data.

32. Standardising the Response Instead of Only the Extract

For decades, botanical science has concentrated on standardising ingredients. The next frontier may be standardising biological response models.

Imagine a common clinical protocol:

1. baseline physiology;
2. standardised cognitive stress challenge;
3. endocrine response;
4. autonomic response;
5. cognitive performance;
6. recovery period;
7. repeated assessment after supplementation.

Different adaptogenic ingredients could then be compared against the same physiological challenge. Researchers might finally begin to answer which adaptogen is primarily neuroendocrine, which preserves cognition, which improves recovery, which works primarily in highly stressed subjects and which has little measurable effect.

33. The Future Commercial Claim May Be "Resilience"

Consumers increasingly understand that stress cannot simply be removed from modern life. Occupational workload, family responsibilities, intensive exercise, disrupted sleep and information overload are structural features of contemporary living.

That changes the commercial proposition.

> **Old proposition: "Feel less stressed."**
> **Emerging proposition: "Function better under stress and recover more effectively afterwards."**

The second proposition is scientifically more interesting and potentially relevant to executives, shift workers, students, athletes, active older adults, high-performance professionals and consumers exposed to sustained cognitive demand. But it requires much stronger evidence and jurisdiction-specific claim assessment.

34. What Consumers Should Look for

What exact botanical species is present?

Not merely "ginseng" or "rhodiola blend".

Which plant part is used?

Root, leaf, fruit and rhizome are not interchangeable.

Is the extract standardised?

And to what?

Is the actual extract clinically studied?

Not merely the botanical species in general.

Is the clinically relevant dose provided?

A trademarked ingredient at one-tenth of its studied dose remains underdosed.

Are safety precautions clearly stated?

A manufacturer that emphasises efficacy while hiding safety information is not demonstrating scientific maturity.

Is the claim credible?

The stronger the claim, the stronger the evidence should be.

35. What Manufacturers Should Do Differently

The future premium adaptogen category will not be built by adding more herbs. It will be built by increasing evidentiary density.

> **what is present -> how much is present -> how it behaves -> in whom it works -> under what conditions -> for how long -> with what safety profile**

That requires integration of pharmacognosy, analytical chemistry, formulation science, toxicology, clinical research, regulatory affairs, data science and consumer behaviour. Adaptogens are therefore not a simple herbal formulation problem. They are a systems-product-development problem.

36. A Proposed R&D Pipeline for the Next Generation of Adaptogens



5	Mechanistic hypothesis
6	Stress phenotype selection
7	Dose selection
8	Pilot challenge study
9	Wearable + biochemical + psychometric assessment
10	Randomised controlled trial
11	Safety surveillance
12	Regulatory claim strategy

This model is considerably more demanding than contemporary supplement development. It is also considerably more defensible.

37. Research Priorities for 2027-2035

1. What exactly constitutes an adaptogenic clinical endpoint?

There is still no universally accepted biomarker or composite endpoint.

2. Are adaptogenic effects conditional on baseline stress?

Trials should stratify participants by initial stress burden.

3. Are there responder and non-responder phenotypes?

Genetics, microbiome composition, sleep status, sex, age and metabolic health may influence response.

4. Does timing matter?

Circadian pharmacology remains underexplored.

5. Are botanical combinations truly synergistic?

Combination studies need factorial experimental designs.

6. What happens during long-term exposure?

Most trials remain relatively short.

7. Which effects are extract-specific?

Meta-analyses should increasingly avoid treating chemically different extracts as identical interventions.

8. Can wearable physiology demonstrate improved recovery?

This could become one of the defining research questions of the next decade.

38. The Most Important Conceptual Shift

Adaptogens are frequently described as substances that restore "balance". It is an attractive word. But scientifically, balance is vague. Living organisms are never static. A healthier concept is adaptive range.

A resilient organism can move away from baseline when necessary, perform effectively while challenged and return efficiently when the challenge ends.

PROPOSED MODERN DEFINITION

An adaptogenic intervention is one that increases functional resilience to a defined stressor by improving the regulation, tolerance or recovery of interconnected physiological systems without producing disproportionate functional impairment or toxicity.

This definition is deliberately more demanding than most commercial definitions. It should be.

Conclusion

Adaptogens occupy an unusual frontier between ancient medical traditions and twenty-first-century systems biology. Their historical use should neither be dismissed nor accepted uncritically.

Traditional medicine can generate hypotheses. Phytochemistry can characterise interventions. Mechanistic research can identify plausible pathways. Clinical trials can determine whether people actually benefit. And regulatory science must determine what manufacturers may legitimately communicate.

Recent evidence supports clinically meaningful effects for certain standardised preparations - particularly selected ashwagandha and rhodiola extracts - but evidence varies considerably between botanicals, products, endpoints and populations. Contemporary research also exposes important uncertainties concerning long-term safety, botanical identity, extract equivalence and the interpretation of conventional stress biomarkers.

The future of the field should therefore move beyond the question: "Which plants are adaptogens?"

Which intervention? Which stressor? Which consumer? Which physiological system? Which dose? Which measurable outcome? Which recovery trajectory?

That shift changes adaptogens from an imprecise category of stress supplements into something much more scientifically interesting: precision tools for biological resilience.

And that may ultimately prove to be the real scientific legacy of the adaptogenic concept.

Selected References

Arumugam, V., Vijayakumar, V., Balakrishnan, A., Bhandari, R. B., Boopalan, D., Ponnurangam, R., Thirupathy, V. S., & Kuppusamy, M. (2024). Effects of Ashwagandha (Withania somnifera) on stress and anxiety: A systematic review and meta-analysis. Explore, 20(6), 103062. https://doi.org/10.1016/j.explore.2024.103062

European Food Safety Authority. (2026). Health claims under Article 13.

European Medicines Agency. (2008). Reflection paper on the adaptogenic concept. EMEA/HMPC/102655/2007.

European Medicines Agency. (2024). European Union herbal monograph on Rhodiola rosea L., rhizoma et radix.

Federal Institute for Risk Assessment. (2024). Ashwagandha: Food supplements with potential health risks. Communication 39/2024.

Fornalik, M., Malkiewicz, A., Adamczak, D., Nawrocki, F., Zielinska, A., & Mondal, S. A. (2026). Hormonal modulation with Withania somnifera: Systematic review and meta-analysis of randomized-controlled trials.

Luszczak, J., & Kocki, J. (2026). Clinical evidence for the adaptogenic effects of Withania somnifera and Rhodiola rosea: A systematic review with molecular interpretation of psychometric outcomes. Annals of Agricultural and Environmental Medicine, 33(1), 3-11.

Panossian, A. G., Efferth, T., Shikov, A. N., et al. (2021). Evolution of the adaptogenic concept from traditional use to medical systems: Pharmacology of stress- and aging-related diseases. Medicinal Research Reviews, 41(1), 630-703. https://doi.org/10.1002/med.21743

Panossian, A., & Wikman, G. (2010). Effects of adaptogens on the central nervous system and the molecular mechanisms associated with their stress-protective activity. Pharmaceuticals, 3, 188-224. https://doi.org/10.3390/ph3010188

Such, S., Puchalski, C., Kogut, L., & Zagula, G. (2026). System-level, molecular and cellular mechanisms of selected plant adaptogens - A review. Nutrients, 18(6), 931. https://doi.org/10.3390/nu18060931

Wang, X., Yang, X., Gao, Z., Zeng, J., & Liu, Y. (2025). The effect of Rhodiola rosea supplementation on endurance performance and related biomarkers: A systematic review and meta-analysis. Frontiers in Nutrition, 12, 1645346. https://doi.org/10.3389/fnut.2025.1645346

World Health Organization. (2025). Global Traditional Medicine Strategy 2025-2034.

Online source access

https://doi.org/10.1016/j.explore.2024.103062
https://www.efsa.europa.eu/en/topics/health-claims-art-13
https://www.ema.europa.eu/en/adaptogenic-concept-scientific-guideline
https://www.ema.europa.eu/en/medicines/herbal/rhodiolae-roseae-rhizoma-et-radix
https://www.bfr.bund.de/cm/349/ashwagandha-food-supplements-with-potential-health-risks.pdf
https://pubmed.ncbi.nlm.nih.gov/41740946/
https://pubmed.ncbi.nlm.nih.gov/41906501/
https://doi.org/10.1002/med.21743
https://doi.org/10.3390/ph3010188
https://doi.org/10.3390/nu18060931
https://doi.org/10.3389/fnut.2025.1645346
https://www.who.int/publications/i/item/9789240113176

Scientific and Regulatory Note

This article discusses nutritional, phytochemical and pharmacological research and is intended for scientific, educational and product-development purposes. The term "adaptogen" does not represent a universally harmonised regulatory category. Botanical ingredients and associated claims must be individually assessed according to applicable food, food-supplement, herbal-medicinal-product and advertising legislation in each target jurisdiction. The discussion of biological mechanisms or published clinical research does not constitute authorisation of any corresponding commercial health or medicinal claim.